Chimeric antigen receptor T cell therapy for hematologic and solid cancers

Tangerman, Meindert (2020) Chimeric antigen receptor T cell therapy for hematologic and solid cancers. Bachelor's Thesis, Life Science and Technology.

Preview	Text bLST_2020_TangermanM.pdf Download (917kB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (125kB)

Abstract

Chimeric antigen receptors have shown dramatic improvements in the survival of patients with hematologic cancer. Clinical trials have shown that CAR T cells are safe and feasible for patients with solid tumors, but have shown limited results. The aim of this thesis is to determine why CAR T cell therapy works well for hematologic malignancies, but not for solid tumors. This has been assessed by looking at the efficacy, persistence and toxicity of CAR T-cells in hematologic and solid cancers. CAR T cells need to overcome additional obstacles in solid tumors. The first obstacle is the lack of specific antigen target for solid tumors. Solid tumors rarely express unique TAA’s because of tumor heterogeneity. Secondly, CAR T cells show poor trafficking towards solid tumor sites. A match between adhesins, chemokines and chemokine receptors is needed for effective trafficking, which is often lacking in solid tumors. The third hurdle obstacle is the immunosuppressive tumor environment. The TME makes CAR T cell treatment for solid tumors challenging, as the it impedes the CAR T proliferation and their ability to engage with their target antigen. The last obstacle involves the poor persistence of CAR T cells in solid tumors. Finally, novel strategies that might help overcome the obstacles in solid cancers have been highlighted

Item Type:	Thesis (Bachelor's Thesis)
Supervisor name:	Bremer, E.
Degree programme:	Life Science and Technology
Thesis type:	Bachelor's Thesis
Language:	English
Date Deposited:	14 May 2020 08:21
Last Modified:	14 May 2020 08:21
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/21882

Actions (login required)

View Item